Compare BioNano Genomics Inc (BNGO) vs Sea Limited (SE) Price & Performance

Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.

BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.

SE trades at $110.66, down 0.43% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth, reaching $22.94B in 2025, and improving profitability with a net income margin of 6.36%. Recent earnings beat expectations in Q1 2026, but insider sales have drawn media attention. Cash flow turned positive in 2025 at $2.34B, reflecting operational strength.

Outlook remains positive with a consensus price target of $131, implying 18% upside. Risks include competitive pressures in Southeast Asia and execution on growth investments. Analyst sentiment is strongly bullish with 70% buy ratings, though high valuation multiples and recent insider selling warrant caution for near-term volatility.